12:00 AM
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Raxone idebenone regulatory update

Santhera withdrew an MAA for Raxone idebenone to treat Leber's hereditary optic neuropathy (LHON). The company said it plans to submit a new MAA that includes "emerging clinical evidence of efficacy," but declined to disclose a timeline. Santhera said that it originally planned to request re-examination of a negative January...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >